FTC ex­pands phar­ma scruti­ny to ear­ly-stage deals, forc­ing Sanofi to drop Pompe dis­ease part­ner­ship with Maze

The Fed­er­al Trade Com­mis­sion said it would seek to block Sanofi’s pro­posed li­cens­ing deal for Maze Ther­a­peu­tics’ clin­i­cal-stage Pompe dis­ease treat­ment, lead­ing the French phar­ma …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER